Compare Enveric Biosciences Inc (ENVB) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Las Vegas Sands Corp. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Las Vegas Sands Corp. trades at $36.41 (market cap $23.38B). The key difference: Las Vegas Sands Corp. is far larger — about 3438.2× Enveric Biosciences Inc's market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Las Vegas Sands Corp. for 72 Days on average.
| ENVB | LVS | |
|---|---|---|
Market Cap | $6.80M | $23.38B |
Volume | 64,867 | 6,994,661 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $69.49 |
52-Week Low | $1.27 | $35.81 |
Typical Hold Time | 14 Days | 72 Days |
Enterprise Value | -$1.49M | $35.27B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
LVS trades at $35.81, down 1.38% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported revenue of $13.02B in 2025 with a net income margin of 12.59%, and recent earnings show mixed results with a Q2 2026 miss. Analysts maintain a strong buy consensus with a $59.78 price target, indicating significant upside potential from current levels.
The outlook for LVS is positive based on solid fundamentals and analyst optimism, but risks include high debt levels and reliance on Macao's tourism sector. Near-term performance may hinge on Q3 2026 earnings and ongoing stock repurchases, while long-term growth is supported by non-gaming expansions and community initiatives in Macao.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
